Sorin Group Announces First World Implant of Crown PRT Heart Valve
New stented aortic bioprosthesis with outstanding ease of use and performance successfully implanted in Austria
Wed Sep 17 2014
Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today the first world implant of its CROWN PRT bioprosthetic aortic valve. The implant was performed in Austria at the Salzburg University Clinic by Prof. Rainald Seitelberger, M.D., and Christian Dinges, M.D.
“Our first experience with CROWN PRT has been extremely positive,” said Professor Seitelberger. “The short two-minute rinse time proved very convenient to streamline intraoperative handling and save on aortic clamp time. The visible commissural markers and the smooth sewing cuff facilitated valve suturing into position. The valve adapted perfectly to the aortic annulus ensuring excellent stability.”
“During the implant, CROWN PRT demonstrated very good pressure gradients as measured by transesophageal echocardiography,” continued Professor Seitelberger. “A meaningful number of implantations will be required to thoroughly assess the valve’s overall performance. However, this first implant is very promising.”
CROWN PRT is the latest advancement in stented aortic bioprosthesis technology, featuring surgeon-friendly design, optimal hemodynamics and the patented Phospholipid Reduction Treatment (PRT) to bolster durability through mitigation of calcium uptake1.
“The CROWN PRT implant performed by Professor Seitelberger and his team represents a key successful step to strategically grow our presence in the tissue heart valve segment worldwide,” said Michel Darnaud, President, Cardiac Surgery Business Unit, Sorin Group. “The most rewarding aspect of this implant is to see Sorin’s innovative technology deliver on its promise of greater standards both for physicians and patients.”